A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma

Inclusion Criteria: * Must have a histologically definitive diagnosis of MIUC at each study site and who must have received nivolumab after radical resection * Must present at least once to the study site after nivolumab treatment or must have survival data Exclusion Criteria: * Participants who underwent only partial resection for MIUC * Participants treated with chemotherapy, radiotherapy, biologics (anticancer agents), intravesical chemotherapy, or Bacillus Calmette-Guérin therapy from the time of radical resection of MIUC to the start of nivolumab * Participants previously treated with immune checkpoint inhibitors prior to nivolumab treatment Other protocol-specific inclusion/exclusion criteria apply.